Dermagnostix develops groundbreaking diagnostics for dermatology to advance clinical practice and improve patients’ lives. One third of the population suffers from at least one skin condition. Skin diseases impair patients’ quality of life more drastically than cancer and diabetes. Biologicals and small-molecule inhibitors have created an unprecedented potential for precision medicine. Diagnostics is lagging behind. Game-changing translational research meets cutting-edge technology – Dermagnostix provides unique diagnostic tests for unmet clinical needs in dermatology on a fully automated portable laboratory. With PsorX, Dermagnostix launches the first in-class molecular test for differential diagnosis of psoriasis and eczema.